VACH

Voyager Acquisition Corp Class A Ordinary Shares
VACH

1 day
0.00%
5 days
0.00%
1 month
0.00%
3 months
0.00%
6 months
0.00%
Year to date
0.00%
1 year
0.00%
5 years
0.00%
10 years
0.00%
 

About: Voyager Acquisition Corp is a blank check company.

Financials Shell Companies
0
Funds holding %
of 7,312 funds
–
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

2.64% more ownership

Funds ownership: 79.21% [Q4 2024] → 81.85% (+2.64%) [Q1 2025]

5% more capital invested

Capital invested by funds: $201M [Q4 2024] → $211M (+$9.87M) [Q1 2025]

9% less funds holding

Funds holding: 45 [Q4 2024] → 41 (-4) [Q1 2025]

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for VACH.

See Analyst Rankings

Financial journalist opinion

Neutral
GlobeNewsWire
1 month ago
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
Neutral
GlobeNewsWire
1 month ago
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
Neutral
GlobeNewsWire
1 month ago
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies Industry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
See News Rankings
Charts implemented using Lightweight Charts™